Lupin Limited (BOM:500257)
India
· Delayed Price · Currency is INR | Market Cap | 889.07B |
| Revenue (ttm) | 227.08B |
| Net Income (ttm) | 32.82B |
| Shares Out | 456.70M |
| EPS (ttm) | 71.69 |
| PE Ratio | 27.16 |
| Forward PE | 22.05 |
| Dividend | 12.00 (0.62%) |
| Ex-Dividend Date | Jul 16, 2024 |
| Volume | 73,165 |
| Average Volume | 39,708 |
| Open | 1,934.20 |
| Previous Close | 1,932.50 |
| Day's Range | 1,921.25 - 1,954.15 |
| 52-Week Range | 1,531.15 - 2,403.45 |
| Beta | 0.31 |
| RSI | 42.93 |
| Earnings Date | Aug 4, 2025 |
About Lupin
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women’s health, central nerv... [Read more]
Financial Performance
In 2024, Lupin's revenue was 227.08 billion, an increase of 13.48% compared to the previous year's 200.11 billion. Earnings were 32.82 billion, an increase of 71.41%.
Financial StatementsNews
Lupin shares in focus as company signs respiratory drug deal in China with Sino Universal
Lupin Limited announced on June 16 that it has entered into a license and supply agreement with Sino Universal Pharmaceuticals for the commercialization of Tiotropium Dry Powder Inhaler (18 mcg/capsul...
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extend...
Lupin to present Phase 1 data on LNP7457 cancer drug at ASCO 2025
Global pharmaceutical major Lupin Limited will present the Phase 1a clinical trial data of its experimental oncology drug LNP7457, a PRMT5 inhibitor, at the American Society of Clinical Oncology (ASCO...
Lupin and SteinCares sign license and supply agreement for Ranibizumab in Latin America
Lupin Limited has signed a license and supply agreement with SteinCares, a Latin America-based specialty healthcare company, for the commercialization of its biosimilar ranibizumab. The agreement cove...
Lupin secures FDA approval for Rivaroxaban 10 mg, 15 mg and 20 mg tablets
Lupin Limited has recently informed exchanges that the company received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Riva...
Lupin launches Tolvaptan tablets in the US for ADPKD treatment
Lupin Limited, a global pharmaceutical company, has announced the launch of its generic Tolvaptan Tablets in the United States following approval from the U.S. Food and Drug Administration (FDA). The ...
Lupin launches Eslicarbazepine Acetate Tablets in the US
Lupin Limited has announced the launch of Eslicarbazepine Acetate Tablets in the U.S. market. The product is available in 200 mg, 400 mg, 600 mg, and 800 mg strengths. The launch follows the U.S. Food...
Lupin extends slump sale of API R&D and OTC business to June 30, 2025
Lupin Limited has announced a revised timeline for the transfer of its API R&D division and Over-the-Counter (OTC) Consumer Healthcare business. In a regulatory filing on April 30, 2025, the company s...
Lupin receives U.S. FDA approval for Tolvaptan tablets with 180-day exclusivity
Lupin Limited shares are in focus today following the announcement that the company has received U.S. FDA approval for its generic version of Tolvaptan Tablets, used for treating autosomal dominant po...
Lupin receives EIR from US FDA for its injectable manufacturing facility in Nagpur
Lupin Limited has recently informed exchanges that the company received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its injectable manufa...
Lupin shares tumble nearly 3% after US court setback in Myrbetriq patent case
Shares of Lupin Ltd fell sharply by 2.85% to ₹1,955.50 on Tuesday after the company lost a crucial patent litigation case in the United States related to the bladder medication Myrbetriq. The stock de...
Lupin: Business Model, Q3 FY25 Earnings, Promoter Details, and Shareholding Pattern
Lupin Limited is a prominent Indian multinational pharmaceutical company headquartered in Mumbai, India. Known for its innovation-led approach, Lupin develops and commercializes a wide range of brande...
Lupin shares fall over 6% today as Trump reportedly hints at possible pharma tariffs
Shares of Lupin Ltd dropped 6.27% to ₹1,964.40 on Friday, down ₹131.30 from the previous close of ₹2,095.70, after reports stated that U.S. President Donald Trump and his administration is considering...
Lupin shares jump 6% as U.S. spares pharma exports from 26% tariff
Lupin Ltd. shares jumped 6% after the U.S. administration confirmed that pharmaceutical products would be exempt from the newly imposed 26% reciprocal tariff on Indian goods. The exemption alleviates ...
Lupin Digital Health launches post-procedure home care guide in collaboration with American College of Cardiology
Lupin Digital Health (LDH), the digital therapeutics arm of Lupin Limited, has launched a comprehensive Post-Procedure Home-Based Care Guide to support cardiac patients in their recovery journey after...
Lupin receives U.S. FDA approval for 10 mg Amifampridine Tablets
Global pharmaceutical leader Lupin Limited has secured tentative approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Amifampridine Tablets, 10 mg. This approval paves the wa...
Lupin share price surges over 1.50% after US launch of Rivaroxaban, brokerages bullish
Shares of Lupin Ltd. (NSE: LUPIN) surged 1.57% to ₹2,061.80 in early trade today following the company’s US launch of generic Rivaroxaban 2.5mg tablets (gXarelto). The stock opened at ₹2,049.80, hit a...
Lupin launches FDA-approved Rivaroxaban Tablets USP, 2.5 mg in the US
Global pharmaceutical leader Lupin Limited has announced the launch of Rivaroxaban Tablets USP, 2.5 mg in the U.S. market. This follows the final approval of its Abbreviated New Drug Application (ANDA...
Lupin shares surge 2.35% as US FDA issues Establishment Inspection Report (EIR) for Somerset facility
Shares of Lupin Ltd surged over 2% on February 24 after the company announced that it has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its Som...
Lupin’s Somerset plant gets FDA approval following successful inspection
Global pharmaceutical giant Lupin Limited has announced that its Somerset, New Jersey manufacturing facility has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administ...
Lupin gets USFDA nod for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03%
Lupin Limited has secured approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% (21 mcg/...
Lupin and Natco Pharma gets USFDA nod for Generic Bosentan tablets
Lupin Limited (Lupin) and its alliance partner Natco Pharma Limited (Natco) have received approval from the U.S. Food and Drug Administration (FDA) for Natco’s Abbreviated New Drug Application (ANDA) ...
Lupin completes acquisition of 42.61% stake in Sunsure Solarpark
Lupin Limited has announced the successful acquisition of a 42.61% equity stake in Sunsure Solarpark Seventeen Private Limited, as part of its strategic investment in renewable energy initiatives. The...
Lupin acquires Huminsulin from Eli Lilly to strengthen its diabetes portfolio
Lupin Limited, a global pharmaceutical leader, announced the acquisition of the Huminsulin® range from Eli Lilly and Company to enhance its diabetes treatment portfolio in India. The acquisition inclu...
Lupin confirms tentative US FDA approval for Type-2 Diabetes drug Janumet generic
Lupin Limited has clarified reports regarding a recent news item about the company receiving US FDA approval. The company confirmed that it has received tentative approval from the US FDA for its gene...